Patents for A61K 49 - Preparations for testing in vivo (35,376)
05/2004
05/21/2004WO2004042353A2 Identifying therapeutic compounds based on their physical-chemical properties
05/21/2004WO2004042074A2 Methods for the identification of agents that modulate the structure and processing of a membrane bound precursor protein
05/21/2004WO2004041328A2 Pharmaceutical identification
05/21/2004WO2004041298A1 Liposomal composition comprising haptotactic peptides
05/21/2004WO2004041213A2 Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein
05/21/2004WO2004041070A2 Mri probes of membrane potential
05/21/2004WO2004022709A3 Epitope sequences
05/21/2004WO2003103587A3 Compounds or agents that inhibit and induce the formation of focal microvessel dilatations
05/21/2004WO2003103569A3 Toluidine blue o drug substance and use thereof for in vivo staining and chemotherapeutic treatment of dysplastic tissues
05/21/2004CA2504922A1 Methods for the identification of agents that modulate the structure and processing of a membrane bound precursor protein
05/21/2004CA2504870A1 Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein
05/21/2004CA2504452A1 Pharmaceutical identification
05/21/2004CA2504334A1 Identifying therapeutic compounds based on their physical-chemical properties
05/20/2004US20040097901 Methods for embolizing vascular sites with an embolizing composition
05/20/2004US20040097415 Controlling blood glucose concentration; amylin antagonist
05/20/2004US20040097403 Linkable sialyl lewis x analogs
05/20/2004US20040096662 Embolization
05/20/2004US20040096514 For treatment of skin contour deficiencies, Gastro-esophageal reflux disease, urinary incontinence, and urinary reflux disease, using the injectable compositions.
05/20/2004US20040096511 Magnetically guidable carriers and methods for the targeted magnetic delivery of substances in the body
05/20/2004US20040096396 Screening in vivo or in vitro using compounds that are selective for E- selectin binding with no significant ability to bind to P-selectin.
05/20/2004US20040096395 Using magnetic resonance imaging to directly map neuronal activity
05/19/2004EP1419789A2 Preparation of a lipid blend and a phospholipid suspension containing the lipid blend, and contrast agents based on these
05/19/2004EP1419788A1 Contrast agent for the identification of lymph nodes
05/19/2004EP1419787A1 Contrast agent for the identification of lymph nodes
05/19/2004EP1419237A2 Animal model for fatty acid amide-related neurobehaviors
05/19/2004EP1418808A1 Imaging marker transgenes
05/19/2004EP0730433B1 Ultrasonic spectral contrast imaging
05/19/2004CN1498116A Agents for measuring pyrimidine metabolizability
05/19/2004CN1150030C 重组人甲胎蛋白及其用途 And its use of recombinant human alpha-fetoprotein
05/18/2004US6738658 Medical optical imaging scanner using multiple wavelength simultaneous data acquisition for breast imaging
05/18/2004US6737040 Method and antibody for imaging breast cancer
05/18/2004US6737039 Administering luteinizing hormone releasing hormone (lhrh) antagonist in an amount and for a period of time sufficient to reduce breast density in the subject prior to generating an image of breast tissue of the subject
05/18/2004US6737038 Contacting potential inhibitor and tagged inhibitor of beta-amyloid production with macromolecule containing binding site specific for tagged inhibitor, separating bound inhibitor, determining inhibitory concentration
05/13/2004WO2004039414A1 Method and apparatus for determining effectiveness of sunscreens and other skin preparations in shielding human skin from uva radiation
05/13/2004WO2004039335A2 Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
05/13/2004WO2004039148A1 Nonbacterial prostatitis model animal
05/13/2004WO2004019995A3 Method and apparatus for producing contrast agents for magnetic resonance imaging
05/13/2004WO2004017943A3 Non-vesicular cationic lipid formulations
05/13/2004US20040093623 Non-human animal disease models
05/13/2004US20040092825 Techniques for identifying molecular structures and treating cell types lining a body lumen using fluorescence
05/13/2004US20040092820 Device and process for quantifying bodies by means of ultrasound
05/13/2004US20040092812 Methods and contrast agents useful in quantifying nitric oxide
05/13/2004US20040092493 Method for ameliorating male erectile dysfunction
05/13/2004US20040091426 Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes
05/13/2004US20040091424 Diagnostic data input unit for entering diagnostic data including the clinical testing data and clinical findings of the patient; a pathophysiologic condition pattern analyzing unit for analyzing the pathophysiologic condition of diabetes
05/13/2004CA2504346A1 Method and apparatus for determining effectiveness of sunscreens and other skin preparations in shielding human skin from uva radiation
05/12/2004EP1418523A2 Diagnosis support system for diabetes
05/12/2004EP1417485A2 Phenotypic effects of ubiquinone deficiencies and methods of screening thereof
05/12/2004EP1417183A1 Multidentate aza ligands able to complex metal ions and the use thereof in diagnostics and therapy
05/12/2004EP1417153A1 N,n-dinitramide salts as solubilizing agents for biologically active agents
05/12/2004EP1416974A1 Gas microsphere liposome composites
05/12/2004EP1416965A2 Assay method for alzheimer's disease
05/12/2004EP1416934A2 Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics
05/12/2004EP1416914A1 Expandable gastric retention device
05/12/2004EP1416846A2 Method and device for determining a characteristic value relating to the blood circulation of modified tissue regions in organs of living beings
05/12/2004EP1077731A4 Intramolecularly-quenched near infrared fluorescent probes
05/12/2004EP0910415B1 Fluoro-labelled anthracycline and anthracyclinone derivatives
05/12/2004EP0904113B1 Microencapsulated fluorinated gases for use as imaging agents
05/12/2004EP0792156B1 Medicaments for the prevention or treatment of vascular hemorrhaging
05/12/2004EP0710261B1 Biodegradable particles
05/12/2004CN1496239A Patch for screening sensitivity state of subject with respect to allergen and use thereof
05/12/2004CN1149165C Coatings for production of hyperpolarized noble gases
05/11/2004US6733744 Indole compounds as minimally invasive physiological function monitoring agents
05/11/2004CA2222974C Magnetic resonance imaging agents for the detection of physiological agents
05/11/2004CA2222581C Oligonucleotide tags for sorting and identification
05/06/2004WO2004038381A2 Methods for drug discovery, disease treatment, and diagnosis using metabolomics
05/06/2004WO2004038039A2 Optical imagiong of renilla luciferase reporter gene expression in living organisms
05/06/2004WO2004037997A2 Fragments and activity of rel protein in m. tuberculosis adn other uses thereof
05/06/2004WO2004037801A1 Piperazinyl and diazapanyl benzamides and benzthioamides
05/06/2004WO2004037314A2 Patch and kit containing delayed-type hypersensitivity inducer
05/06/2004WO2004037259A1 Dosage form that is safeguarded from abuse
05/06/2004WO2004037210A2 Functional mri agents for cancer imaging
05/06/2004WO2004037192A2 Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases
05/06/2004WO2004005484A3 Snrks as modifiers of chk and branching morphogenesis and methods of use
05/06/2004WO2003096990A9 Protein cages for the delivery of medical imaging and therapy
05/06/2004WO2003079966A3 Photo-active backbone cyclized somatostatin analogs for photodynamic therapy and imaging
05/06/2004WO2002066074A3 Method for assessing food allergenicity
05/06/2004US20040087930 Methods for embolizing vascular sites with an embolizing composition
05/06/2004US20040087829 Radioactive seed with multiple markers and method for using same
05/06/2004US20040087588 Parp inhibitors
05/06/2004US20040087517 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
05/06/2004US20040087497 CD10-activated prodrug compounds
05/06/2004US20040086503 High-affinity human anti-IGF-IR antibodies that could be used to treat diseases in humans
05/06/2004US20040086479 Can be chemically modified for different biomedical applications such as tissue engineering applications, wound management, contrast agents vehicles, drug delivery vehicles, etc.
05/06/2004US20040086462 Radio-opaque polymer biomaterials
05/06/2004US20040086461 Radio-opaque polymer biomaterials
05/06/2004US20040086459 Efficient for back scattering ultrasound energy
05/06/2004US20040086458 Radio-opaque polymer biomaterials
05/06/2004US20040086457 Orally ingestible baked radiopaque product having a dry food texture
05/06/2004US20040086456 Optically measuring the amount of deposited sebum by being in contact with skins
05/06/2004US20040086454 In situ radioimmunoassay; immunotherapy; coupling modified peptide to monoclonal antibodies
05/06/2004EP1415001A2 Nucleotide compositions comprising photocleavable markers and methods of preparation thereof
05/06/2004EP1414994A2 Microorganisms and cells for diagnosis and therapy of tumors
05/06/2004EP1414963A2 Lipid-associated molecules
05/06/2004EP1414499A2 Non-invasive tumor imaging by tumor-targeted bacteria
05/06/2004EP1414411A1 Pulmonary formulation comprising silicon particles
05/06/2004EP1414299A2 Substantially homogeneous bio-affecting material having a pre-determined ratio of bioaffecting component to cell targeting component, the method for making such a material and the method of its use
05/06/2004EP0998476B1 1,4,7,10-tetraazabicyclo 8.2.2]tetradecan-2-one, a process for the preparation thereof and the use thereof for the preparation of tetraazamacrocycles
05/06/2004EP0840727B1 3-hydroxy-2(1h)-pyridinone chelating agents
05/06/2004EP0831932B1 Novel targeted compositions for diagnostic and therapeutic use